113 related articles for article (PubMed ID: 28884474)
1. Recognition by natural killer cells of N6-isopentenyladenosine-treated human glioma cell lines.
Ciaglia E; Laezza C; Abate M; Pisanti S; Ranieri R; D'alessandro A; Picardi P; Gazzerro P; Bifulco M
Int J Cancer; 2018 Jan; 142(1):176-190. PubMed ID: 28884474
[TBL] [Abstract][Full Text] [Related]
2. Antiglioma effects of N6-isopentenyladenosine, an endogenous isoprenoid end product, through the downregulation of epidermal growth factor receptor.
Ciaglia E; Abate M; Laezza C; Pisanti S; Vitale M; Seneca V; Torelli G; Franceschelli S; Catapano G; Gazzerro P; Bifulco M
Int J Cancer; 2017 Feb; 140(4):959-972. PubMed ID: 27813087
[TBL] [Abstract][Full Text] [Related]
3. N6-isopentenyladenosine, an endogenous isoprenoid end product, directly affects cytotoxic and regulatory functions of human NK cells through FDPS modulation.
Ciaglia E; Pisanti S; Picardi P; Laezza C; Malfitano AM; D'Alessandro A; Gazzerro P; Vitale M; Carbone E; Bifulco M
J Leukoc Biol; 2013 Dec; 94(6):1207-19. PubMed ID: 23847096
[TBL] [Abstract][Full Text] [Related]
4. N6-isopentenyladenosine affects cytotoxic activity and cytokines production by IL-2 activated NK cells and exerts topical anti-inflammatory activity in mice.
Ciaglia E; Pisanti S; Picardi P; Laezza C; Sosa S; Tubaro A; Vitale M; Gazzerro P; Malfitano AM; Bifulco M
Pharmacol Res; 2014 Nov; 89():1-10. PubMed ID: 25063359
[TBL] [Abstract][Full Text] [Related]
5. Cannabinoid receptor CB1 regulates STAT3 activity and its expression dictates the responsiveness to SR141716 treatment in human glioma patients' cells.
Ciaglia E; Torelli G; Pisanti S; Picardi P; D'Alessandro A; Laezza C; Malfitano AM; Fiore D; Pagano Zottola AC; Proto MC; Catapano G; Gazzerro P; Bifulco M
Oncotarget; 2015 Jun; 6(17):15464-81. PubMed ID: 26008966
[TBL] [Abstract][Full Text] [Related]
6. N6-isopentenyladenosine inhibits aerobic glycolysis in glioblastoma cells by targeting PKM2 expression and activity.
Pagano C; Coppola L; Navarra G; Avilia G; Savarese B; Torelli G; Bruzzaniti S; Piemonte E; Galgani M; Laezza C; Bifulco M
FEBS Open Bio; 2024 May; 14(5):843-854. PubMed ID: 38514913
[TBL] [Abstract][Full Text] [Related]
7. MICA/NKG2D-mediated immunogene therapy of experimental gliomas.
Friese MA; Platten M; Lutz SZ; Naumann U; Aulwurm S; Bischof F; Bühring HJ; Dichgans J; Rammensee HG; Steinle A; Weller M
Cancer Res; 2003 Dec; 63(24):8996-9006. PubMed ID: 14695218
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxic activity of allogeneic natural killer cells on U251 glioma cells in vitro.
Guo M; Wu T; Wan L
Mol Med Rep; 2016 Jul; 14(1):583-9. PubMed ID: 27175912
[TBL] [Abstract][Full Text] [Related]
9. TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells.
Eisele G; Wischhusen J; Mittelbronn M; Meyermann R; Waldhauer I; Steinle A; Weller M; Friese MA
Brain; 2006 Sep; 129(Pt 9):2416-25. PubMed ID: 16891318
[TBL] [Abstract][Full Text] [Related]
10. Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition.
Di Modica M; Sfondrini L; Regondi V; Varchetta S; Oliviero B; Mariani G; Bianchi GV; Generali D; Balsari A; Triulzi T; Tagliabue E
Oncotarget; 2016 Jan; 7(1):255-65. PubMed ID: 26595802
[TBL] [Abstract][Full Text] [Related]
11. Human NK cells are alerted to induction of p53 in cancer cells by upregulation of the NKG2D ligands ULBP1 and ULBP2.
Textor S; Fiegler N; Arnold A; Porgador A; Hofmann TG; Cerwenka A
Cancer Res; 2011 Sep; 71(18):5998-6009. PubMed ID: 21764762
[TBL] [Abstract][Full Text] [Related]
12. Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells.
Schwinn N; Vokhminova D; Sucker A; Textor S; Striegel S; Moll I; Nausch N; Tuettenberg J; Steinle A; Cerwenka A; Schadendorf D; Paschen A
Int J Cancer; 2009 Apr; 124(7):1594-604. PubMed ID: 19089914
[TBL] [Abstract][Full Text] [Related]
13. Reactive oxygen species- and DNA damage response-dependent NK cell activating ligand upregulation occurs at transcriptional levels and requires the transcriptional factor E2F1.
Soriani A; Iannitto ML; Ricci B; Fionda C; Malgarini G; Morrone S; Peruzzi G; Ricciardi MR; Petrucci MT; Cippitelli M; Santoni A
J Immunol; 2014 Jul; 193(2):950-60. PubMed ID: 24913980
[TBL] [Abstract][Full Text] [Related]
14. RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo.
Friese MA; Wischhusen J; Wick W; Weiler M; Eisele G; Steinle A; Weller M
Cancer Res; 2004 Oct; 64(20):7596-603. PubMed ID: 15492287
[TBL] [Abstract][Full Text] [Related]
15. N6-Isopentenyladenosine promoted HeLa cell apoptosis through inhibitions of AKT and transforming growth factor β-activated kinase 1 activation.
Li M; Qi Y; Wei J; Lu L; Zhao X; Zhou L
Tumour Biol; 2017 Mar; 39(3):1010428317695966. PubMed ID: 28345459
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of therapeutic effects of natural killer (NK) cell-based immunotherapy in mice using in vivo apoptosis bioimaging with a caspase-3 sensor.
Lee HW; Singh TD; Lee SW; Ha JH; Rehemtulla A; Ahn BC; Jeon YH; Lee J
FASEB J; 2014 Jul; 28(7):2932-41. PubMed ID: 24736413
[TBL] [Abstract][Full Text] [Related]
17. Sensitivity of glioma and fetal brain cell lines to natural killer cytolysis in a monolayer assay.
Kazimer RM; Whisler RL; Stephens RE; Pearl DK; Yates AJ
J Neurooncol; 1989 Jul; 7(2):145-50. PubMed ID: 2778490
[TBL] [Abstract][Full Text] [Related]
18. N6-isopentenyladenosine dual targeting of AMPK and Rab7 prenylation inhibits melanoma growth through the impairment of autophagic flux.
Ranieri R; Ciaglia E; Amodio G; Picardi P; Proto MC; Gazzerro P; Laezza C; Remondelli P; Bifulco M; Pisanti S
Cell Death Differ; 2018 Feb; 25(2):353-367. PubMed ID: 29027991
[TBL] [Abstract][Full Text] [Related]
19. The isoprenoid derivative N
Ciaglia E; Grimaldi M; Abate M; Scrima M; Rodriquez M; Laezza C; Ranieri R; Pisanti S; Ciuffreda P; Manera C; Gazzerro P; D'Ursi AM; Bifulco M
Br J Pharmacol; 2017 Jul; 174(14):2287-2301. PubMed ID: 28419419
[TBL] [Abstract][Full Text] [Related]
20. The histone deacetylase inhibitor trichostatin a promotes apoptosis and antitumor immunity in glioblastoma cells.
Höring E; Podlech O; Silkenstedt B; Rota IA; Adamopoulou E; Naumann U
Anticancer Res; 2013 Apr; 33(4):1351-60. PubMed ID: 23564772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
